Experts say screening at-risk adults for latent TB likely yields moderate benefits.
New data from the Centers for Disease Control and Prevention (CDC) shows that there were 3,250 likely cases of severe MERS-CoV in the Middle East between Sept 2012 and Jan 2016. This number is 2.3-fold higher than current laboratory confirmed cases, suggesting that the disease is more widespread than previously thought.
SAB Biotherapeutics, Inc., of Sioux Falls, S.D., announced today that its experimental human antibody treatment for MERS-CoV—called SAB-301—has entered human trials, the first potential treatment for the disease to do so.
A study yesterday in the Journal of Infectious Diseases suggests that although the Ebola outbreak originating in West Africa in 2013 was the deadliest to date, that strain of Ebola virus (EBOV) did not possess more aerosol stability than a strain of 1976 EBOV.
In its weekly yellow fever situation report, the World Health Organization (WHO) today noted 73 more cases of the disease in Angola, bringing that country's suspected cases to 3,625.
Utah health officials today announced the first known Zika death in the continental United States, in a Salt Lake County resident who died in late June.
Saudi Arabia's Ministry of Health (MOH) reported a new MERS-CoV infection, involving an 80-year-old woman from Jeddah who is a household contact of an earlier confirmed patient, and the World Health Organization (WHO) yesterday filled in more details about 13 recently reported cases from the country, 5 linked to a Riyadh hospital outbreak and at least 3 that appear to be linked to small clusters in Jeddah and Najran.
The World Health Organization (WHO) today issued a statement offering new details on 6 cases of MERS-CoV reported on Jun 19 and 20 in Saudi Arabia. Four of the cases are related to the current outbreak at King Khalid University Hospital in Riyadh.
Following the development of a rapid diagnostic test for multidrug-resistant tuberculosis (MDR-TB) strains, the World Health Organization (WHO) today recommended a shorter treatment regimen for patients with uncomplicated MDR-TB infections.
Ahead of its upcoming meeting, the National Science Advisory Board for Biosecurity (NSABB) has posted a draft of a working group's recommendations to guide federal officials in evaluating proposed gain-of-function (GOF) studies on H5N1 flu and other dangerous pathogens, and an outside company tasked with crafting a risk-benefit analysis of GOF research has posted its final report.
